The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Dig Liver Dis
; 50(7): 675-681, 2018 07.
Article
em En
| MEDLINE
| ID: mdl-29576495
ABSTRACT
BACKGROUND:
The effectiveness of vedolizumab in real-world practice is under evaluation, while its role in inflammatory bowel disease-associated spondyloarthritis is still unclear.AIMS:
To report real-world data about the effectiveness of vedolizumab on intestinal and articular symptoms after 10 and 22 weeks of treatment.METHODS:
Web-based data from the cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD) were extracted to perform a prospective multicentre observational study.RESULTS:
163 patients (84 with Crohn's disease and 79 with ulcerative colitis) were included. At week 10, a steroid-free remission was achieved in 71 patients (43.6%), while at week 22 a steroid-free remission was obtained in 40.8% of patients. A response on articular symptoms was reported after 10 weeks of treatment in 17 out of 43 (39.5%) patients with active spondyloarthritis at baseline, and in 10 out of 22 (45.4%) patients at week 22. The only factor associated with articular response was the coexistence of clinical benefit on intestinal symptoms (at week 10 OR 8.471, pâ¯=â¯0.05; at week 22 OR 5.600, pâ¯=â¯0.08).CONCLUSIONS:
Vedolizumab showed good effectiveness after 10 and 22 weeks of treatment. A subset of patients reported improvement also on articular symptoms, probably as a consequence of the concomitant control of gut inflammation.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fármacos Gastrointestinais
/
Doenças Inflamatórias Intestinais
/
Anticorpos Monoclonais Humanizados
/
Intestinos
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article